SunTrust Robinson Believes Express Scripts (NASDAQ: ESRX) Still Has Room to Grow

By Jason Carr

In a report released yesterday, David S Macdonald from SunTrust Robinson reiterated a Buy rating on Express Scripts (NASDAQ: ESRX), with a price target of $95. The company’s shares closed yesterday at $80.09, close to its 52-week high of $81.04.

According to, Macdonald is a 4-star analyst with an average return of 8.1% and a 73.7% success rate. Macdonald covers the Services sector, focusing on stocks such as American Renal Associates Holdings Inc, Encompass Health Corporation, and Fresenius Medical Care Corp.

Currently, the analyst consensus on Express Scripts is Moderate Buy and the average price target is $84.57, representing a 5.6% upside.

In a report issued on January 9, Robert W. Baird also reiterated a Buy rating on the stock with a $92 price target.

Express Scripts’ market cap is currently $45.36B and has a P/E ratio of 13.19. The company has a book value ratio of 2.8501.

Based on the recent corporate insider activity of 78 insiders, corporate insider sentiment is neutral on the stock.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Express Scripts Holding Co. engages in the provision of integrated pharmacy benefit management services. Its services include network-pharmacy claims processing, home delivery pharmacy care, specialty pharmacy care, benefit-design consultation, drug utilization review, formulary management, and medical and drug data analysis services.